ArticleInternational journal of cancer2010
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Article in International journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- Activating p53 function by targeting RLIP.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Targeting RLIP with CRISPR/Cas9 controls tumor growth.Carcinogenesis · 2021Article
- Article
- Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities.Nature reviews. Urology · 2019Review
- Topical 2'-Hydroxyflavanone for Cutaneous Melanoma.Cancers · 2019Article
- A potential function of RLIP76 in the ovarian corpus luteum.Journal of ovarian research · 2019Review
- Rlip depletion prevents spontaneous neoplasia in TP53 null mice.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells.Journal of kidney cancer and VHL · 2018Article
- RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.Pharmaceutical research · 2017Review
- PharmGKB summary: sorafenib pathways.Pharmacogenetics and genomics · 2017Review
- Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2Neoplasia (New York, N.Y.) · 2017Article
- Alpinumisoflavone suppresses tumour growth and metastasis of clear-cell renal cell carcinoma.American journal of cancer research · 2017Article
- Autophagy, a double-edged sword in anti-angiogenesis therapy.Medical oncology (Northwood, London, England) · 2016Review
- RLIP76 Targeted Therapy for Kidney Cancer.Pharmaceutical research · 2015Review
- The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide.European journal of drug metabolism and pharmacokinetics · 2015Article
- Article
- Knockdown of RLIP76 expression by RNA interference inhibits proliferation, enhances apoptosis, and increases chemosensitivity to daunorubicin in U937 leukemia cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.British journal of pharmacology · 2014Article
- Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.Journal of experimental & clinical cancer research : CR · 2014Article
- Sunitinib resistance in renal cell carcinoma.Journal of kidney cancer and VHL · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
RLIP76 is a stress-responsive membrane protein implicated in the regulation of multiple cellular signaling pathways. It represents the predominant glutathione-conjugate (GS-E) transporter in cells. We have shown that RLIP76 plays a crucial role in defending cancer cells from radiation and chemotherapeutic toxin-mediated apoptosis, and that its inhibition by antibodies or depletion by siRNA or antisense causes apoptosis in a number of cancer cell types. We demonstrated for the first time that the striking anti-neoplastic effects with no evident toxicity in terms of either weight loss or metabolic effects are also demonstrable for the antibody, antisense and siRNA in a renal cell xenografts model of Caki-2 cells (Singhal et al., Cancer Res., 2009, 69: 4244). Present studies were performed to determine if RLIP76 targeting is more broadly applicable in other kidney cancer cell lines, to compare the signaling effects of RLIP76 antisense with kinase inhibitors used in treatment of renal cell carcinoma, and to determine whether kinase inhibitors were substrates for transport by RLIP76. Results of these studies show that sorafenib as well as sunitinib are substrates for transport by RLIP76 thus are competitive inhibitors of GS-E transport. Furthermore, kinase inhibition in the ERK as well as PI3K pathways by RLIP76 depletion is more profound and consistent and is more widely apparent in a number of renal carcinoma cell lines. These studies offer strong support for our overall hypothesis that RLIP76 is an overarching anti-apoptosis mechanism that, if inhibited, can be more broadly effective in the treatment of renal cell carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.